Cargando…
Disruptor of telomeric silencing 1-like promotes ovarian cancer tumor growth by stimulating pro-tumorigenic metabolic pathways and blocking apoptosis
Ovarian cancer is the leading cause of gynecological malignancy-related deaths. Current therapies for ovarian cancer do not provide meaningful and sustainable clinical benefits, highlighting the need for new therapies. We show that the histone H3K79 methyltransferase disruptor of telomeric silencing...
Autores principales: | Chava, Suresh, Bugide, Suresh, Edwards, Yvonne J. K., Gupta, Romi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8275629/ https://www.ncbi.nlm.nih.gov/pubmed/34253709 http://dx.doi.org/10.1038/s41389-021-00339-6 |
Ejemplares similares
-
Betacellulin promotes tumor development and EGFR mutant lung cancer growth by stimulating the EGFR pathway and suppressing apoptosis
por: Chava, Suresh, et al.
Publicado: (2022) -
Co-targeting of specific epigenetic regulators in combination with CDC7 potently inhibit melanoma growth
por: Chava, Suresh, et al.
Publicado: (2022) -
CBX5 loss drives EGFR inhibitor resistance and results in therapeutically actionable vulnerabilities in lung cancer
por: Bugide, Suresh, et al.
Publicado: (2023) -
The BRD9/7 Inhibitor TP-472 Blocks Melanoma Tumor Growth by Suppressing ECM-Mediated Oncogenic Signaling and Inducing Apoptosis
por: Mason, Lawrence David, et al.
Publicado: (2021) -
Prognostic and therapeutic value of disruptor of telomeric silencing-1-like (DOT1L) expression in patients with ovarian cancer
por: Zhang, Xiaoxue, et al.
Publicado: (2017)